DrugBuyers.Com: Similar suffering?

I am acutally lucky to be in the health care field, so I am able to do research outside of the docs office and understand the medical jargon.

To answer to some of the replies:

- yes I have considered diet modifications. I have tried every combination you could think of. What one of the posters was referring to (wheat/barley/oats) is called Celiacs disease. I have not been tested for this but I have tried eliminating anything with these ingredients (and you would be surprised at how many food has minor amounts of these ingredients) but it has not helped. I have tried to eliminate dairy, fats, alcohols and everything else under the sun and it doesn't help.

- I have not had any abdominal surgery (such as appendectomy) so that would rule out scarring

- basically, I am just going to keep trying to find something. I think that it is going to be a common illness presenting in an abnormal way (and that's why no one can figure it out yet).

Yes Ultracet and Zoloft have interactions. If you go to Discovery Health and click on the drug interaction link. It really depends on the dose of Zoloft you are taking (the higher the dose, the more the risk). Also, the docs had me on two other medications that increased the risks for seizures (especially when past head trauma was in the history and I've had two severe head traumas)....so basically I stopped taking everything. Here is what it said:

Major Interaction -- Drug-Drug
sertraline and acetaminophen-tramadol

GENERALLY AVOID: The coadministration of selective serotonin reuptake inhibitors (SSRIs) with tramadol, which has weak serotonin reuptake inhibiting effect, may potentiate the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5HT1A receptors. Patients receiving this combination may also have an increased risk of seizures. Pharmacokinetically, coadministration with certain SSRIs, namely fluoxetine, paroxetine and possibly sertraline, may result in decreased plasma concentrations of the active O-demethylated (M1) metabolite of tramadol due to inhibition of CYP450 2D6, the isoenyzme responsible for the formation of the metabolite. The clinical significance of this potential interaction is unknown. However, M1 is thought to possess up to 6 times the analgesic effect of tramadol, thus diminished therapeutic response to tramadol should be considered. MANAGEMENT: In general, the concomitant use of SSRIs and tramadol should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk. Patients treated with the combination should be closely monitored for signs and symptoms of excessive serotonergic activity such as CNS irritability, altered consciousness, confusion, myoclonus, ataxia, abdominal cramping, hyperpyrexia, shivering, pupillary dilation, diaphoresis, hypertension, and tachycardia.